Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase its manufacturing capacity to up to 50 million doses a year, supporting Takeda's goal to produce 100 million doses annually by 2030. The collaboration leverages Takeda's existing facility in Germany and its partnership with IDT Biologika GmbH.